

Phosphoinositide acyl chain saturation drives CD8⁺ effector T cell signaling and function

In the format provided by the authors and unedited

Supplementary Table 1. Demographic and disease characteristics of patients with malignant melanoma

Demographics	
No. participants (%)	13 (100)
Median age (range), years	55 (46-90)
Sex	
female - no. (%)	4 (31)
male - no. (%)	9 (69)
Disease and treatment characteristics	
Site of primary manifestation	
Skin - no. (%)	12 (92)
Uvea - no. (%)	1 (8)
Tumor stage	
Stage III - no. (%)	1 (8)
Stage IV - no. (%)	12 (92)
Lesion sites	
1 - no. (%)	4 (31)
2 - no. (%)	5 (38)
3 - no. (%)	4 (31)
Treatment type	
Pembrolizumab - no. (%)	4 (31)
Nivolumab - no. (%)	1 (8)
Nivolumab/Ipilimumab - no. (%)	8 (61)
Response	
Complete remission - no. (%)	1 (8)
Partial remission - no. (%)	5 (38)
Stable disease - no. (%)	1 (8)
Progressive disease - no. (%)	5 (38)
Not available - no. (%)	1 (8)
Immune-related adverse events	
No - no. (%)	4 (31)
Yes - no. (%)	9 (69)
Median follow up duration (days)	318 (184-484)

Supplementary Table 2. Nucleotide sequences of gRNA for CRISPR-Cas9-mediated gene deletion

Gene	Sequences
<i>Cd1pt</i>	Mm.Cas9.GGACTCCTAGACGCTTTCTGA Mm.Cas9.TCGGATCTACTATACCTCTA Mm.Cas9.CAGCACTCACCGATAAGGTT
<i>Zap70</i>	Mm.Cas9.CCATCGAGCGCCAATCAA Mm.Cas9.GCACCAAGTTTGACACGCTC
<i>Control</i>	Mm.Cas9.GCGAGGTATTCGGCTCCGCG